Market Research Logo

Paratek Pharmaceuticals Inc (PRTK) - Financial and Strategic SWOT Analysis Review

Paratek Pharmaceuticals Inc (PRTK) - Financial and Strategic SWOT Analysis Review

- SWOT Analysis Review provides you an provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Paratek Pharmaceuticals Inc (Paratek) develops and commercializes therapies based on tetracycline chemistry. Nuzyra (Omadacycline), the company’s lead product candidate is an USFDA approved broad spectrum antibiotic for the treatment of adults with community acquired bacterial pneumonia, acute bacterial skin and skin structure infections caused by susceptible bacteria. Its other product Seysara (sarecycline) is also an USFDA approved drug for the treatment of inflammatory acne vulgaris in patients with aged nine or older. Omadacycline is in Phase II clinical trials for the treatment of female patients with uncomplicated urinary tract infection and acute pyelonephritis. Paratek is headquartered in Boston, Massachusetts, the US.

Paratek Pharmaceuticals Inc Key Recent Developments

Aug 06,2019: Paratek Pharmaceuticals generates net revenues of $2.0 Million in the second quarter of 2019
Jun 25,2019: Paratek Pharmaceuticals promotes Evan Loh, M.D. to Chief Executive Officer; Michael Bigham to Assume Role of Executive Chairman
Mar 18,2019: Paratek Pharmaceuticals announces management change
Feb 27,2019: Paratek Pharmaceuticals reports fourth quarter and full year 2018 financial results
Feb 13,2019: Drugs targeting metastatic cancers, opioid addiction are among additional specialty drugs available through AllianceRx Walgreens Prime

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Paratek Pharmaceuticals Inc - Key Facts
Paratek Pharmaceuticals Inc - Key Employees
Paratek Pharmaceuticals Inc - Key Employee Biographies
Paratek Pharmaceuticals Inc - Major Products and Services
Paratek Pharmaceuticals Inc - History
Paratek Pharmaceuticals Inc - Company Statement
Paratek Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Paratek Pharmaceuticals Inc - Business Description
Paratek Pharmaceuticals Inc - Corporate Strategy
Paratek Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Paratek Pharmaceuticals Inc - Strengths
Paratek Pharmaceuticals Inc - Weaknesses
Paratek Pharmaceuticals Inc - Opportunities
Paratek Pharmaceuticals Inc - Threats
Paratek Pharmaceuticals Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Paratek Pharmaceuticals Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Aug 06, 2019: Paratek Pharmaceuticals generates net revenues of $2.0 Million in the second quarter of 2019
Jun 25, 2019: Paratek Pharmaceuticals promotes Evan Loh, M.D. to Chief Executive Officer; Michael Bigham to Assume Role of Executive Chairman
Mar 18, 2019: Paratek Pharmaceuticals announces management change
Feb 27, 2019: Paratek Pharmaceuticals reports fourth quarter and full year 2018 financial results
Feb 13, 2019: Drugs targeting metastatic cancers, opioid addiction are among additional specialty drugs available through AllianceRx Walgreens Prime
Nov 06, 2018: Paratek Pharmaceuticals reports third quarter 2018 financial results
Aug 02, 2018: Paratek Pharmaceuticals announces second quarter 2018 financial results
May 09, 2018: Paratek Pharmaceuticals Reports First Quarter 2018 Financial Results
Apr 20, 2018: Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases
Apr 13, 2018: Paratek Names Rolf K. Hoffman As Board Director
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Paratek Pharmaceuticals Inc, Key Facts
Paratek Pharmaceuticals Inc, Key Employees
Paratek Pharmaceuticals Inc, Key Employee Biographies
Paratek Pharmaceuticals Inc, Major Products and Services
Paratek Pharmaceuticals Inc, History
Paratek Pharmaceuticals Inc, Other Locations
Paratek Pharmaceuticals Inc, Subsidiaries
Paratek Pharmaceuticals Inc, Key Competitors
Paratek Pharmaceuticals Inc, Ratios based on current share price
Paratek Pharmaceuticals Inc, Annual Ratios
Paratek Pharmaceuticals Inc, Annual Ratios (Cont...1)
Paratek Pharmaceuticals Inc, Interim Ratios
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Paratek Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Paratek Pharmaceuticals Inc, Performance Chart (2014 - 2018)
Paratek Pharmaceuticals Inc, Ratio Charts
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report